Article

Ankylosing spondyltitis instruments lacking in patient's perspective

The classic disease-specific instruments for evaluating ankylosing spondylitis (AS) are geared toward the needs of researchers and clinicians. Therefore, they often do not cover aspects of the disease that are important to patients and those factors are neglected.

The classic disease-specific instruments for evaluating ankylosing spondylitis (AS) are geared toward the needs of researchers and clinicians. Therefore, they often do not cover aspects of the disease that are important to patients and those factors are neglected.

Boonen and associates used the International Classification of Functioning, Disability, and Health (ICF), a universal approach to understanding and classifying functioning and health, as a starting place to qualitatively identify the concepts that are important to functioning for persons with AS. The investigators also explored whether the concepts that matter most to patients are covered by existing AS-specific instruments.

Based on information gathered during 4 focus group interviews of 19 patients each, the investigators concluded that the classic AS-specific assessment instruments do not cover aspects of functioning that are important to patients. The main areas in which the patients thought that these instruments could be improved included the influence of AS on socializing, leisure pursuits, and environmental and personal variables.

The authors noted that using the list of ICF categories important for patients might help broaden the scope of problems in functioning with AS for researchers and for physicians assessing health in those with the disease.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.